What is Risankizumab used for?
Risankizumab is used to treat moderate to severe plaque psoriasis and is also being investigated for use in treating Crohn�s disease and ulcerative colitis.
How does Risankizumab work?
Risankizumab works by targeting and inhibiting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that contributes to skin cell overproduction in psoriasis.
What are the side effects of Risankizumab?
Common side effects include upper respiratory infections, fatigue, and headache. Serious side effects may include infections or allergic reactions.
How is Risankizumab administered?
Risankizumab is administered as a subcutaneous injection, typically given every 12 weeks after an initial loading dose.
Can Risankizumab be used for conditions other than psoriasis?
Yes, Risankizumab is being studied for other conditions, such as Crohn's disease and ulcerative colitis, due to its ability to target IL-23 and reduce inflammation.
What should I do if I miss a dose of Risankizumab?
If you miss a dose, take it as soon as you remember. If it�s nearly time for the next dose, skip the missed dose and resume your normal schedule. Contact your healthcare provider for further guidance.
Is Risankizumab safe during pregnancy?
Risankizumab should only be used during pregnancy if the potential benefits outweigh the risks. Consult your healthcare provider if you are pregnant or planning to become pregnant.
How effective is Risankizumab for treating plaque psoriasis?
Risankizumab has shown strong effectiveness in clinical trials for reducing the severity of plaque psoriasis, with many patients experiencing significant skin improvement.
Can Risankizumab cause an increase in infections?
Yes, as an immunosuppressive medication, Risankizumab can increase the risk of infections. It is important to monitor for signs of infection and contact your doctor if any occur.
How does Risankizumab help with Crohn's disease?
Risankizumab works by reducing inflammation in the intestines by targeting IL-23, which plays a role in the immune response in Crohn�s disease.